Clinical trial · Interventional
[11C]Acetate PET in Patients With Glioma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): low enrollment
Summary
Brief summary (as posted)
At each point that the patient will have \[11C\]-Acetate PET study, this will be compared with standard clinical MR imaging. Abbreviations: XRT - radiation therapy; TMZ - temozolomide (chemotherapy) Quantitative Image Data Analysis: The \[11C\]-Acetate uptake in tumor sites from images will be analyzed qualitatively by visual assessment, quantitatively using a standard uptake value (SUV) in the tumor relative to the contralateral normal brain, and the parameters obtained by compartmental modeling of dynamic data.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioma | Glioma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [11C]Acetate Brain Imaging | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- [11C]Acetate Brain Imaging
- description
- \[11C\]Acetate will be administered The patient will have one intravenous line placed prior to \[11C\]Acetate administration. The patient will receive the low-dose CT portion of a PET/CT scan, after which \[11C\]Acetate will be administered intravenously over approximately 1 min at a dose of 0.3 mCi/kg (maximum 30 mCi) and followed by a saline flush. The injection and imaging procedure will be terminated in any patient who exhibits anaphylaxis, significant dyspnea or chest pain. The administering physician will stay with the patient for at least 15 min after injection and will remain in the Clinical PET Facility through the duration of the imaging procedure.
- interventionNames
- Other: [11C]Acetate Brain Imaging
Primary outcomes (1)
- measure
- Visual differences from normal brain in patients with grades 2, 3 or 4 gliomas
- timeFrame
- Every 3 months for 24 months
- description
- Visual assessment and SUV with standard clinical MR imaging assessment.using T2/FLAIR and gadolinium enhancement.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female, age 18 and older, of any ethnic group * Spanish-speaking patients will be eligible * Histological diagnosis of glioma or * Brain MR imaging suggestive of a glioma or 2HG \> 2mM by MR spectroscopy in patients who have not had a surgical procedure to establish the diagnosis. * Karnofsky Performance status \> 70% * Negative serum pregnancy test or child bearing potential terminated by surgery, radiation, menopause or current use of two approved methods of birth control * Patient able and willing to provide informed consent Exclusion Criteria: * Patient or legal parent/guardian unable to provide informed consent * Psychiatric or addictive disorders that preclude obtaining informed consent * Karnofsky Performance status \< 70% * NYHA class III and IV congestive heart failure * Unstable angina * Pregnant or lactating women * Women of childbearing potential who refuse a pregnancy test
References
Publications (0)
Data not yet available